For the quarter ending 2025-09-30, KNSA made $180,855K in revenue. $18,333K in net income. Net profit margin of 10.14%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 180,855 | 156,797 | 101,197 | 112,214 |
| Cost of goods sold | 20,257 | 18,603 | 14,240 | 20,109 |
| Collaboration expenses | 63,307 | 52,418 | 34,495 | 29,307 |
| Research and development | 24,166 | 18,753 | 30,775 | 26,057 |
| Selling, general and administrative | 49,104 | 46,863 | 39,609 | 46,399 |
| Total operating expenses | 156,834 | 136,637 | 119,118 | 121,872 |
| Income (loss) from operations | 24,021 | 20,160 | -17,920 | -9,658 |
| Other income | 3,136 | 2,717 | 2,293 | 2,457 |
| Income (loss) before income taxes | 27,157 | 22,877 | -15,627 | -7,201 |
| Provision for income taxes | 8,722 | 5,045 | -2,331 | 5,492 |
| Net income (loss) | 18,435 | 17,832 | -13,296 | -12,693 |
| Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax | -102 | 112 | 3,043 | 89 |
| Total other comprehensive income (loss) | -102 | 112 | 3,043 | 89 |
| Total comprehensive income (loss) | 18,333 | 17,944 | -10,253 | -12,604 |
| Earnings per share, basic | 0.25 | 0.24 | -0.18 | -0.18 |
| Earnings per share, diluted | 0.23 | 0.23 | -0.18 | -0.18 |
| Weighted average number of shares outstanding, basic | 74,714,846 | 73,438,530 | -35,653,583 | 71,726,685 |
| Weighted average number of shares outstanding, diluted | 80,035,400 | 77,942,082 | -35,653,583 | 71,726,685 |
Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA)